Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders

Biohaven Ltd. (NYSE:BHVN) is one of the Best 52-Week Low Stocks to Buy According to Analysts.. On June 10, Biohaven Ltd. (NYSE:BHVN) announced that it has started a research collaboration with Bexorg, Inc. targeting central nervous system disorders.

Bexorg, which is a techbio company, has a platform that can revive and study whole human and pig brains using artificial blood. This technology helps them see how drugs affect actual brain tissue. The platform produces deep data about how genes and proteins behave in disease and health.

Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders

A pharmacist in a white coat with a range of drugs on shelves behind her.

Both companies will use this technology to help design and test new therapies for CNS conditions. As a result of this collaboration, two Biohaven Ltd. (NYSE:BHVN) preclinical programs will benefit from these unique brain studies. Bexorg’s approach offers a big leap ahead of normal lab models.

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company that develops and commercializes treatments for diseases in immunology, neuroscience, and oncology.

While we acknowledge the potential of BHVN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BHVN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.